KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Ionis Pharmaceuticals (IONS) EBIT (2016 - 2026)

Ionis Pharmaceuticals (IONS) has disclosed EBIT for 18 consecutive years, with -$117.4 million as the latest value for Q1 2026.

  • For Q1 2026, EBIT rose 20.04% year-over-year to -$117.4 million; the TTM value through Mar 2026 reached -$352.2 million, up 25.44%, while the annual FY2025 figure was -$79.7 million, 83.22% up from the prior year.
  • EBIT hit -$117.4 million in Q1 2026 for Ionis Pharmaceuticals, up from -$214.5 million in the prior quarter.
  • Across five years, EBIT topped out at $139.8 million in Q2 2025 and bottomed at -$214.5 million in Q4 2025.
  • Average EBIT over 5 years is -$102.2 million, with a median of -$114.1 million recorded in 2023.
  • Year-over-year, EBIT tumbled 1710.21% in 2024 and then skyrocketed 311.55% in 2025.
  • Ionis Pharmaceuticals' EBIT stood at -$208.0 million in 2022, then surged by 97.06% to -$6.1 million in 2023, then crashed by 1710.21% to -$110.8 million in 2024, then plummeted by 93.52% to -$214.5 million in 2025, then soared by 45.25% to -$117.4 million in 2026.
  • According to Business Quant data, EBIT over the past three periods came in at -$117.4 million, -$214.5 million, and -$160.2 million for Q1 2026, Q4 2025, and Q3 2025 respectively.